Inflammatory bowel disease
Conditions
Interventions
Gold Standard:Diagnosis of IBD (Ulcerative Colitis and Crohn's Disease) requires comprehensive analysis combining clinical manifestations, laboratory tests, endoscopic examination, imaging studies, an
anemia (possible iron/B12 deficiency in CD)
leukocytosis.
- Stool tests: Elevated calprotectin/lactoferrin (inflammatory markers), exclusion of infections (e.g., C. difficile).
- Serological tests (auxiliary): p-ANCA (more common in UC), ASCA (
pelvic MRI or endoscopic ultrasound (EUS) for perianal lesions.
5. Histopathological Features:
- UC: Crypt abscesses, superficial inflammation (mucosa/submucosa), basal plasmacytosis.
- CD: Transmural
Index test:Method: Nano-LAMP-microfluidic chip technology
Blood tests: Complete blood count, serum albumin, electrolytes, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)
Stool tests:
Sponsors
Shanghai Science and Technology Commission
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients who meet the diagnostic criteria for UC/CD in Western medicine; 2. Patients with polyps diagnosed by colonoscopy and resected; 3. No other underlying diseases; 4. No history of long-term medication for other chronic diseases; 5. Patients who meet the diagnostic criteria for other diseases of the intestinal tract in Western medicine, including intestinal polyps, colorectal cancer, chronic inflammatory bowel disease, irritable bowel syndrome, and other intestinal disorders; 6. Patients who have signed an informed consent form; 7. Age Between 18-80 years old.
Exclusion criteria
Exclusion criteria: 1. Co-existing with other immune system diseases, such as immune hepatitis, connective tissue disease, systemic lupus erythematosus, scleroderma, etc.; 2. History of long-term drug taking due to other diseases, such as gastric ulcer, duodenal ulcer, chronic gastritis, intestinal tuberculosis, tuberculous peritonitis, chronic diarrhea, chronic pancreatitis, etc.; 3. Co-infected with infectious diseases such as AIDS, hepatitis B, tuberculosis, etc.; 4. During pregnancy, Lactating women; 5. Patients who are unable to complete the short-term dietary questionnaire due to mental and intellectual factors; 6. Patients who have participated in other oral drug clinical trials in the last 1-3 months; 7. Patients who are unwilling to accept return visits and continuous testing; 8. Patients who are younger than 18 years old or older than 80 years old.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| sensitivity;specificity;repeatability;limit of detection; | — |
Countries
China
Contacts
Public ContactWeiwei Liu
Longhua Hospital, Shanghai University of Traditional Chinese Medicine
Outcome results
None listed